Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ AptarGroup, Inc. (ATR) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Instruments & Supplies
$134.75
+5.64 (4.37%)Did ATR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if AptarGroup is one of their latest high-conviction picks.
Based on our analysis of 2 Wall Street analysts, ATR has a bullish consensus with a median price target of $150.00 (ranging from $140.00 to $220.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $134.75, the median forecast implies a 11.3% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for ATR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | Wells Fargo | Gabe Hajde | Overweight | Maintains | $145.00 |
| Mar 20, 2026 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Jan 6, 2026 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Nov 3, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 3, 2025 | Baird | Outperform | Maintains | $N/A | |
| Sep 10, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Sep 4, 2025 | Keybanc | Overweight | Initiates | $N/A | |
| Aug 4, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 4, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| Jul 18, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Jul 15, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| May 6, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 22, 2025 | Raymond James | Outperform | Maintains | $N/A | |
| Feb 10, 2025 | Raymond James | Outperform | Reiterates | $N/A | |
| Feb 10, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 10, 2025 | Baird | Outperform | Maintains | $N/A | |
| Jan 7, 2025 | Raymond James | Outperform | Initiates | $N/A | |
| Jan 6, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 28, 2024 | Baird | Outperform | Maintains | $N/A | |
| Oct 15, 2024 | Wells Fargo | Overweight | Maintains | $N/A |
The following stocks are similar to AptarGroup based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AptarGroup, Inc. has a market capitalization of $8.25B with a P/E ratio of 21.4x. The company generates $3.87B in trailing twelve-month revenue with a 10.0% profit margin.
Revenue growth is +10.8% quarter-over-quarter, while maintaining an operating margin of +11.1% and return on equity of +14.8%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Designs and manufactures drug delivery and dispensing solutions.
AptarGroup operates through three segments: Pharma, Beauty and Home, and Food and Beverage. The company generates revenue by providing specialized packaging, dispensing systems, and active material science solutions tailored to various markets, including pharmaceuticals and consumer goods.
Founded in 1940 and headquartered in Crystal Lake, Illinois, AptarGroup has a global presence with manufacturing facilities across North America, Europe, Asia, and South America. The company focuses on innovation and sustainability, aiming to meet diverse customer needs in healthcare and consumer products.
Healthcare
Medical Instruments & Supplies
13,500
Mr. Stephan B. Tanda
United States
1993
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aptar has released its 2025 Corporate Sustainability Report, detailing its sustainability initiatives and goals. Investors may find insights on the company's environmental strategies.
Aptar's 2025 Corporate Sustainability Report signals commitment to ESG practices, potentially attracting socially responsible investors and influencing stock performance based on sustainability priorities.
AptarGroup, Inc. (ATR) presented at the 16th Annual Wells Fargo Industrials & Materials Conference, providing insights relevant for investors.
AptarGroup's presentation at a key industry conference can signal strategic insights, potential growth opportunities, and market positioning, influencing investor sentiment and stock performance.
AptarGroup, Inc. (ATR) presented at the Jefferies Global Healthcare Conference 2026, highlighting key developments and insights relevant to investors.
AptarGroup's presentation at a major healthcare conference may signal strategic initiatives, potential partnerships, or innovations, influencing investor sentiment and stock performance.
Aptar has been recognized as a CDP Supplier Engagement Leader for the sixth consecutive year, highlighting its commitment to sustainability practices.
Aptar's recognition as a CDP Supplier Engagement Leader indicates strong sustainability practices, potentially enhancing its reputation and attractiveness to socially responsible investors.
Aptar will participate in upcoming investor conferences, indicating potential opportunities for engagement and updates with stakeholders.
Aptar's participation in investor conferences signals potential growth opportunities, market insights, and strategic developments, influencing investor sentiment and stock performance.
AptarGroup (NYSE: ATR) announced a CEO transition at its annual meeting, reported shareholder approval of all ballot items, and provided updates on 2025 performance and early 2026 results.
AptarGroup's CEO transition may signal strategic shifts, while shareholder approvals indicate strong governance. Updates on 2025 and early 2026 performance can influence future stock valuations.
Based on our analysis of 2 Wall Street analysts, AptarGroup, Inc. (ATR) has a median price target of $150.00. The highest price target is $220.00 and the lowest is $140.00.
According to current analyst ratings, ATR has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $134.75. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict ATR stock could reach $150.00 in the next 12 months. This represents a 11.3% increase from the current price of $134.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
AptarGroup operates through three segments: Pharma, Beauty and Home, and Food and Beverage. The company generates revenue by providing specialized packaging, dispensing systems, and active material science solutions tailored to various markets, including pharmaceuticals and consumer goods.
The highest price target for ATR is $220.00 from at , which represents a 63.3% increase from the current price of $134.75.
The lowest price target for ATR is $140.00 from at , which represents a 3.9% increase from the current price of $134.75.
The overall analyst consensus for ATR is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $150.00.
Stock price projections, including those for AptarGroup, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.